Wolfe Josh's Form 4 filing
Eikon Therapeutics, Inc. (EIKN) · filed Feb 6, 2026
- Accession no.
- 0001193125-26-041549
- Filed
- Feb 6, 2026
- Trade date
- Feb 4-6, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 5 non-derivative transactions and 10 derivative transactions. Open-market purchases total $5.00M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Wolfe JoshCIK 0001830001 | Director, 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 4, 2026 | Common Stock | PPurchaseAcquired | +138,888 | $18.00 | +$2,499,984 | 138,888 | Indirect | |
| Feb 4, 2026 | Common Stock | PPurchaseAcquired | +138,888 | $18.00 | +$2,499,984 | 138,888 | Indirect | |
| Feb 6, 2026 | Common Stock | CConversionAcquired | +2,387,705 | –F3,F4 | – | 2,387,705 | Indirect | |
| Feb 6, 2026 | Common Stock | CConversionAcquired | +1,151,540 | –F4,F6,F7 | – | 1,290,428 | Indirect | |
| Feb 6, 2026 | Common Stock | CConversionAcquired | +2,155,765 | –F6,F7,F8,F9,F10 | – | 2,294,653 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 6, 2026 | Common Stock | CConversionDisposed | −1,340,878 | –F3 | – | 0 | Indirect | |
| Feb 6, 2026 | Common Stock | CConversionDisposed | −1,046,827 | –F4 | – | 0 | Indirect | |
| Feb 6, 2026 | Common Stock | CConversionDisposed | −335,521 | –F4 | – | 0 | Indirect | |
| Feb 6, 2026 | Common Stock | CConversionDisposed | −106,785 | –F6 | – | 0 | Indirect | |
| Feb 6, 2026 | Common Stock | CConversionDisposed | −71,190 | –F6 | – | 0 | Indirect | |
| Feb 6, 2026 | Common Stock | CConversionDisposed | −709,234 | –F7 | – | 0 | Indirect | |
| Feb 6, 2026 | Common Stock | CConversionDisposed | −472,822 | –F7 | – | 0 | Indirect | |
| Feb 6, 2026 | Common Stock | CConversionDisposed | −40,677 | –F8 | – | 0 | Indirect | |
| Feb 6, 2026 | Common Stock | CConversionDisposed | −194,510 | –F9 | – | 0 | Indirect | |
| Feb 6, 2026 | Common Stock | CConversionDisposed | −1,376,566 | –F10 | – | 0 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
The Series A Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's initial public offering ("IPO") on a 1-for-7.4578 basis and had no expiration date.
Referenced by the price of 1 transaction in Table I and 1 transaction in Table II.
- F4
The Series A-1 Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's IPO on a 1-for-7.4578 basis and had no expiration date.
Referenced by the price of 2 transactions in Table I and 2 transactions in Table II.
- F6
The Series B Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's IPO on a 1-for-7.4578 basis and had no expiration date.
Referenced by the price of 2 transactions in Table I and 2 transactions in Table II.
- F7
The Series B-1 Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's IPO on a 1-for-7.4578 basis and had no expiration date.
Referenced by the price of 2 transactions in Table I and 2 transactions in Table II.
- F8
The Series C Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's IPO on a 1-for-7.4578 basis and had no expiration date.
Referenced by the price of 1 transaction in Table I and 1 transaction in Table II.
- F9
The Series C-1 Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's IPO on a 1-for-7.4578 basis and had no expiration date.
Referenced by the price of 1 transaction in Table I and 1 transaction in Table II.
- F10
The Series D Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's IPO on a 1-for-7.4578 basis and had no expiration date.
Referenced by the price of 1 transaction in Table I and 1 transaction in Table II.